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Abstract
While treatments that induce DNA damage are commonly used as anti-cancer therapies, the 
mechanisms through which DNA damage produces a therapeutic response are incompletely 
understood. Here we have tested whether medulloblastomas must be competent for apoptosis to be 
sensitive to radiation therapy. Whether apoptosis is required for radiation sensitivity has been 
controversial. Medulloblastoma, the most common malignant brain tumor in children, is a 
biologically heterogeneous set of tumors typically sensitive to radiation and chemotherapy; 80% 
of medulloblastoma patients survive long-term after treatment. We used functional genetic studies 
to determine if the intrinsic apoptotic pathway is required for radiation to produce a therapeutic 
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response in mice with primary, Shh-driven medulloblastoma. We found that cranial radiation 
extended the survival of medulloblastoma-bearing mice and induced widespread apoptosis. 
Expression analysis and conditional deletion studies showed that p53 was the predominant 
transcriptional regulator activated by radiation and was strictly required for treatment response. 
Deletion of Bax, which blocked apoptosis downstream of p53, was sufficient to render tumors 
radiation resistant. In apoptosis-incompetent, Bax-deleted tumors, radiation activated p53-
dependent transcription without provoking cell death and caused two discrete populations to 
emerge. Most radiated tumor cells underwent terminal differentiation. Perivascular cells, however, 
quickly resumed proliferation despite p53 activation, behaved as stem cells, and rapidly drove 
recurrence. These data show that radiation must induce apoptosis in tumor stem cells to be 
effective. Mutations that disable the intrinsic apoptotic pathways are sufficient to impart radiation 
resistance. We suggest that medulloblastomas are typically sensitive to DNA-damaging therapies 
because they retain apoptosis competence.
Introduction
Whether DNA-damaging anti-cancer treatments must induce apoptosis to be clinically 
beneficial remains an unsettled question with important implications. Because resistance to 
apoptosis is recognized as a hallmark of cancer [1, 2], it has been proposed that radiation 
and chemotherapy act through non-apoptotic mechanisms, including mitotic catastrophe, 
senescence, and necrosis [3, 4]. If tumor cells die through non-apoptotic mechanisms the 
active participation of the tumor cell may not be required; for example injury may 
accumulate until cell viability is compromised. Apoptosis, in contrast, requires the function 
of endogenous molecular pathways within the tumor cell. If apoptosis is required for 
treatment response, resistance to therapy may arise from any mutation that disrupts the 
apoptotic pathways.
Medulloblastoma, the most common malignant brain tumor in children, is an ideal cancer in 
which to examine the role of apoptosis in treatment response, because most 
medulloblastomas are strikingly sensitive to DNA-damaging therapies. Whereas 
medulloblastoma was invariably fatal before the use of external beam radiation (xRT) , 
radiation of the entire neuraxis results in 60% long-term survival [5]. The addition of 
chemotherapy to xRT further increases the 5-year event-free survival (EFS) to 81% [6]. In 
contrast, for children with glioblastoma, xRT and chemotherapy produce a 3-year EFS of 
7% [7]. The biologic basis for the specific sensitivity of medulloblastoma to conventional 
therapy is unknown, and in every molecular subgroup of medulloblastoma, outcomes are 
heterogeneous [8]. Determining the cellular processes required for medulloblastoma to 
respond to xRT may lead to alternative, less toxic therapeutic approaches and to new ways to 
identify and address the 20% of patients with resistant tumors.
Insight into the molecular pathogenesis of medulloblastoma has made it possible to generate 
transgenic mice that develop primary medulloblastoma with high incidence and short latency 
[9–13]. Aberrant activation of the Sonic Hedgehog (SHH) signaling pathway defines a 
molecular subgroup that includes patients with sporadic and familial tumors, overall 28% of 
patients [14]. Constitutive activation of the Shh pathway in neural progenitors in transgenic 
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mice causes tumors that faithfully recapitulate the SHH-subgroup of human 
medulloblastoma, sharing a common site of origin, histology and molecular signature. 
Transgenic, conditional SmoM2 mice, express a mutant, constitutively active allele of the 
Shh receptor component Smoothened, when activated by cre recombinase [15]. Mice with 
the genotype Math1-cre;SmoM2 (M-Smo) express SmoM2 in cerebellar granule neuron 
progenitors and develop medulloblastoma with 100% frequency by postnatal day 12 (P12) 
[16], providing a highly efficient preclinical model. Deleting specific genes in M-Smo mice 
offers a genetic approach to identify molecular determinants of tumor response.
Prior studies in primary tumor models of both medulloblastoma and lymphoma have shown 
that p53 function is essential for treatment effectiveness [17–20]. Many cancers with intact 
p53, however, are treatment resistant. Diverse cellular processes may be engaged by p53 
activation after treatment, including both apoptosis and cell cycle exit [21]. Testing the 
functional role of specific mechanisms that operate downstream of p53 in mediating 
treatment sensitivity may identify new mechanisms of resistance to therapy. Here, we 
directly tested the importance of the intrinsic apoptosis pathway in a primary tumor model in 
vivo. We subjected mice with Shh-driven medulloblastomas to xRT, determined that this 
treatment elicited a p53-dependent response, and then examined the effect of deleting the 
apoptosis gatekeeper protein Bax. While Bax mutations have not been identified in 
medulloblastoma, Bax deletion served in our model as a genetically tractable method of 
blocking apoptosis; numerous genetic and epigenetic events may effectively block apoptosis 
in the human disease. We used this genetic approach to determine if a functional intrinsic 
apoptotic pathway is required for xRT to produce a clinically significant benefit.
We modeled radiation therapy by subjecting M-Smo mice with primary medulloblastoma to 
cranial xRT. We found that 10Gy of radiation, delivered in either 1 dose or in 5 fractions of 2 
Gy, produced a strong anti-tumor effect. Transcriptomic analysis prior to the onset of 
apoptosis demonstrated that xRT induced a pattern of gene expression changes that was 
highly dependent on p53 regulation and included both pro-apoptotic and anti-proliferative 
components. Conditional deletion of either p53 or Bax blocked the therapeutic benefit of 
xRT, demonstrating the importance of p53-induced activation of endogenous apoptotic 
pathways in mediating medulloblastoma treatment sensitivity.
Methods
Mice
All animals were handled and used in accordance with approved practices of the Animal 
Care and Use Committee of the University of North Carolina (IACUC# 13–121). Math1-cre 
mice [46] were shared by David Rowitch (UCSF, San Francisco, CA) and Robert Wechsler-
Reya (Sanford-Burnham Medical Research Institute, La Jolla, CA). Bax floxed (Baxfl/fl) 
mice (strain:6329), SmoM2 mice (strain:5130), and p53 floxed (p53fl/fl) mice (strain:8462) 
were purchased from Jackson Laboratories, Bar Harbor, ME, USA. All mice were 
maintained on a C57/Bl6 background through at least 4 crosses and both sexes were used for 
experiments. Genotypes were determined by PCR using Tail Lysis Buffer (Allele 
Biotechnology, cat#ABP-PP-MT01) and genotyping protocols from Jackson Labs 
(jaxmice.jax.org).
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xRT treatment
Tumor-bearing pups at P12 were administered continuous anesthesia (Isoflurane, 1.5%) for 
4 min. inside a small animal research irradiator (RS 2000, Rad Source Technologies) that 
delivered an x-ray dose of either 2 Gy or 10Gy, centered on the posterior fossa, with the dose 
rate of 2.6 Gy/min. Cranial radiation was achieved by shielding the body of the animal with 
a lead plate. 2Gy doses were repeated daily to a total dose of 10 Gy. Sham-treated mice were 
administered anesthesia without xRT. Mice were heated and monitored while recovering 
from anesthesia and returned to their home cage for survival studies.
Kaplan Meier survival analysis
Tumor-bearing mice were monitored daily for health status and movement abnormalities. 
All mice were euthanized at the onset of symptoms, including 10% weight loss, ataxia or 
lethargy. The age of the animal at the time of harvest due to tumor symptoms was recorded 
as the event-free survival. The Kaplan-Meier method was used to estimate survival and Log 
Rank tests were used to compare survival between experimental groups.
Histology
Tissue was collected for histology at indicated times after xRT and processed for 
immunohistochemistry (IHC) as previously described [24]. Briefly, brains were fixed in 4% 
formaldehyde in PBS for 24 hours then embedded in paraffin and sectioned. IHC was 
performed on paraffin-embedded sections after deparaffinization in Histoclear and 
rehydration in a graded ethanol series, heated to boiling in 10 mM citrate buffer, pH 6.0, in a 
pressure cooker for 15 min. After antigen retrieval, IHC was performed using primary 
antibodies: phosphorylated histone H2AX (γH2AX) (cat#9718, Cell Signaling Technology, 
Danvers, MA, USA), Bax (cat#AF820, Sigma, St. Louis, MO, USA), p53 (cat#2527, Cell 
Signaling Technology), cleaved Caspase 3 (cC3) (cat#9664, Cell Signaling Technology), 
NeuN (cat#MAB377, EMD Millipore, Billerica, MA, USA), p21 (cat#ab109199, Abcam, 
Cambridge, UK), Proliferating Cell Nuclear Antigen (PCNA; cat#2586, Cell Signaling 
Technology), phosphorylated Histone H3 (pH3; cat#9701, Cell Signaling Technology), 
phosphorylated p53 (p-p53 ; cat #9284, Cell Signaling Technology), and Sox2 (cat # 
AB5603, EMD Millipore). H&E-stained sections were prepared using standard techniques. 
TUNEL staining was performed per manufacturer’s protocol (cat#C10245, Life 
technologies, Carlsbad CA). Where indicated, nuclei were counterstained with 4′6-
diamino-2-phenylindole (DAPI; cat#D1306, Life technologies), diluted 200 ng/ml in PBS 
for 5 min. Stained slides were scanned using an Aperio ScanScope XT and imaged using 
Aperio ImageScope software (Aperio, Vista, CA, USA).
Expression arrays and analysis
Tumor tissue was dissected and immediately flash frozen at indicated times after xRT. 
Frozen tissue was homogenized by sonication in RLT buffer (Qiagen), and total RNA was 
purified following manufacturer’s instructions (QIAGEN, cat#74104). RNA was labeled, 
hybridized to Affymetrix Mouse Gene 2.1ST arrays, per manufacturer’s protocol 
(Affymetrix, Santa Clara, CA USA) and scanned by the UNC-Lineberger Genomics core.
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Microarray analysis was performed using R (http://www.r-project.org/) and Bioconductor 
(http://www.bioconductor.org/) for independent SmoM2 mice without radiation (n = 6) and 
SmoM2 mice 2 hours after radiation (n = 6). T-test was used to identify genes that change 
significantly between the two groups. A list of 123 genes identified in this analysis with 
increased RNA abundance after radiation was used to identify potentially enriched biologic 
processes using the GSEA software [47]. The Affymetrix gene expression dataset has been 
deposited in GEO.
For RT-qPCR, cDNA was prepared from total RNA using oligo-dT primers and the 
Superscript III kit (Life Technologies, Cat# 18080400) per manufacturer’s instructions. 
SYBR-green qPCR was then run on cDNA, using primer sequences: p21- 
CAGCAGAATAAAAGGTGCCACA, GACAACGGCACACTTTGCTC; PUMA- 
AGGTGCCTCAATAGCAACCC, CTCCCTGGAGCCCCG, β2 Microglobulin- 
CTCGGTGACCCTGGTCTTTC,TTGAGGGGTTTTCTGGATAGCA, GAPDH- 
AAGAGGGATGCTGCCCTTAC, CGGGACGAGGAAACACTCTC.
In situ hybridization
PUMA and p21 mRNA were detected by in situ hybridization using the RNAScope 2.0 HD 
Brown Assay kit (Cat# 300056, Advanced Cell Diagnostics, Hayward CA, USA). Probes for 
PUMA (Cat# 300031) and p21(Cat# 408551) were obtained from Advanced Cell 
Diagnostics and used per manufacturer’s protocol, including RNAse-free DNAse treatment.
In-vivo treatments
Etoposide—Tumor-bearing pups at P12 were dosed with 5mg/kg etoposide (cat#E1383, 
Sigma) in saline solution containing 1% DMSO. A single 50ul intraperitoneal injection of 
etoposide was given; 8 hours after injection tissue was harvested for histology.
BrdU/EdU labeling—A single 400mg/kg dose of BrdU (cat#B5002, Sigma) and, 2 days 
later, a single dose of 400mg/kg EdU (cat#A10044, Life technologies), both in 100ul of 
saline solution, were given by intraperitoneal injection at time points indicated in text. 
Double labeling was accomplished through standard histological processing using a 
monoclonal primary antibody against BrdU (cat#5292, Cell Signaling Technology) and 
Click-iT® chemistry for labeling of EdU (cat#C10337, Life technologies).
Results
Mouse medulloblastoma, like human medulloblastoma, responds to xRT with increased 
survival time
We have previously shown that a single fraction of 10 Gy induces a wave of apoptosis in M-
Smo medulloblastomas after a latent period of 3–4 hours [22]. To determine if radiation 
produced a sustained regression, consistent with a clinically relevant benefit, we compared 
survival of M-Smo mice with or without xRT. At P12, tumor-bearing mice were randomly 
assigned to receive xRT (n=34) or no treatment (n=23). We subjected mice in the xRT group 
to 10 Gy cranial irradiation, focused on the posterior fossa. Control mice were subjected to 
sham treatment with anesthesia without irradiation. xRT increased median survival from 20 
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to 36 days (p<0.001; Log rank test) with 15% of treated mice surviving disease free for > 
100 days (Figure 1A). A separate set of mice treated with 10 Gy administered as 5 daily 
fractions of 2Gy showed a similar increase in survival (p<0.001; Log rank test; Figure 1A’.)
Histologic analysis demonstrated a temporal pattern of radiation response that was 
consistent from animal to animal. We examined 3 biologic replicates at progressive intervals 
after single-fraction treatment. We found that tumors became less densely cellular by 4 hours 
after treatment with 10Gy xRT, decreased in size by 24 hours, and involuted by 5 days 
(Figure 1B–E). Prior to xRT, rare, scattered tumor cells demonstrated spontaneous DNA 
damage as determined by IHC for γH2AX; after xRT, all tumor cells and adjacent neurons 
stained strongly for γH2AX in 3/3 mice, indicating widespread DNA damage (Figure 1F,G). 
The increased γH2AX signal dissipated by 24 hours after xRT in 3/3 mice as tumor cells 
underwent cell death and neurons completed the repair of DNA damage (Figure 1H,I). 
Tumor cell apoptosis, demonstrated by IHC for cC3, began at 4 hours after xRT in all mice 
examined, and persisted over the first 24 hours after treatment (Figure 1J–M). TUNEL 
staining also demonstrated cell death beginning 4 hours after xRT (Supplementary Fig. 
S1A). Treatment with a single fraction of 2Gy produced similar, but more heterogeneous 
patterns of TUNEL staining, DNA damage and cell death 4 hours after xRT (Supplementary 
Fig. S1B–F). Thus, 2Gy and 10Gy doses of xRT provoked tumor cell apoptosis in mouse 
medulloblastoma after a latent period of less than 4 hours, and a cumulative dose of 10Gy 
significantly extended mouse survival.
The transcriptional response of medulloblastomas to xRT is predominantly driven by p53 
and includes regulators of apoptosis and cell cycle progression
To define the early molecular events mediating the tumor response to xRT, we compared 
mRNA isolated from medulloblastomas 2 hours after xRT or from untreated control tumors. 
10 Gy cranial xRT was administered to tumor-bearing M-Smo mice (n = 6). RNA was 
isolated from tumors 2 hours after treatment, prior to the onset of apoptosis, defined by 
detectable cleavage of caspase 3. For comparison, RNA was isolated from an equal number 
of littermate, sham-treated controls. RNA was analyzed on Affymetrix Mouse Gene 2.1ST 
expression arrays. The mRNA levels of 123 genes were increased by 1.5 fold or greater after 
xRT, with a corrected p-value < 0.01 (Figure 2A). GSEA analysis demonstrated a significant 
concordance between these genes and previously published p53-related gene sets (Figure 2B 
and Supplementary Table 1–3). Previously identified p53 targets demonstrated significantly 
greater fold change after xRT compared to the entire set of genes analyzed (Figure 2C). This 
association was observed for a set of 52 genes that were identified from published literature 
as p53-induced (Supplementary Table 1), and for a set of 163 genes detected in a recent 
GRO-seq analysis of p53 targets (Supplementary Table 2) [23]. As a control, a gene set 
randomly drawn from 10 unrelated MSigDB sets (control gene set, Supplementary Table 4) 
demonstrated no difference in RNA fold change. Ingenuity Pathway Analysis similarly 
identified p53 as the upstream regulator most strongly activated by xRT, with 26/73 
consensus p53 targets up-regulated (p = 1.3x10−19); no other upstream regulators were 
identified with the significance within 3 orders of magnitude. Together, these pathway- and 
gene-specific comparisons demonstrated that xRT-induced RNA changes were highly 
associated with p53 response.
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Among the p53 target genes that were strongly up-regulated in response to xRT were the 
pro-apoptotic genes (Apaf: FC=1.9, p=4.2x10−6; Bax: FC=1.9, p=9.7x10−7; PUMA: 
FC=3.8, p=2.8x10−7), and inhibitors of cell cycle progression (p21/Cdkn1A: FC=3.9, 
p=1.2x10−8). Using quantitative PCR we confirmed that PUMA and p21 mRNA were 
increased 8 and 6 fold, respectively, after xRT (Figure 2D). These data show that xRT 
activated a coherent, reproducible transcriptional profile in medulloblastoma that was driven 
largely by p53 and included genes promoting both cell death and cell cycle arrest.
To confirm the essential role of p53 in the response to xRT in our model, we bred mice with 
conditional alleles of p53 into Math1-cre and SmoM2 lines to generate homozygous, Math1-
cre;SmoM2;p53f/f (M-Smo;p53floxed) mice and heterozygous Math1-cre;SmoM2;p53f/+ 
littermate controls (M-Smo;p53het) . Both genotypes developed tumors with 100% 
frequency by P12. We treated both genotypes with 10 Gy xRT and examined 3 biologic 
replicates of each genotype at specific intervals after treatment. Radiation induced 
homogeneous accumulation of p53 protein in all M-Smo;p53het tumors within 2 hours 
(Figure 3A,B). As expected, in M-Smo;p53floxed tumors, p53 protein was absent from tumor 
cells and only accumulated in endothelial cells of tumor capillaries (Figure 3C,D). Induction 
of both PUMA and p21 after xRT was significantly reduced in 3/3 M-Smo;p53floxed tumors 
(Figure 3E–J). In 3/3 p53-deleted tumors at 4 hours, 24 hours or 5 days after xRT, radiation 
did not provoke widespread apoptosis, although some cell death in stroma was observed at 4 
hours (Figure 3K–M). In contrast, 3/3 M-Smo;p53het tumors responded to xRT with 
precipitous apoptosis, similar to tumors with wild type p53 (data not shown). Proliferation 
was transiently suppressed by xRT in M-Smo;p53floxed tumors, as mitoses were undetectable 
in all tumor 4 hours after radiation (Figure 3N). Mitosis resumed by 24 hours, however, and 
continued at 5 days (Figure 3O,P). Although xRT induced transient cell cycle arrest in M-
Smo;p53floxed tumors, this growth arrest was not sustained. These results show that p53 was 
required for xRT to produce a durable therapeutic response.
The therapeutic effect of xRT requires a functional intrinsic apoptotic pathway
To determine if the intrinsic apoptotic pathway was required for the p53-mediated response 
of medulloblastoma to radiation, we next examined the effect of xRT on tumor-bearing mice 
with conditional deletion of the pro-apoptotic protein Bax. Mice with floxed alleles of Bax 
were bred into a Math1-cre and SmoM2 background to generate homozygous, Math1-
cre;SmoM2;Baxf/f (M-Smo;Baxfloxed) mice and homozygous Math1-cre;SmoM2;Bax+/+ 
littermate controls (M-Smo;BaxWT). Bax protein was absent in M-Smo;Baxfloxed tumors, 
and Bax deletion did not alter tumor histology (Supplementary Figure S2A–D). IHC for 
cC3, however, demonstrated that spontaneous apoptosis was markedly reduced 
(Supplementary Figure S2E,F). We did not detect a statistically significant effect of Bax 
deletion on the survival of mice with Math1-cre;SmoM2-driven tumors (Supplementary 
Figure S2G). We previously found that Bax deletion accelerated tumorigenesis in the more 
slowly tumorigenic ND2:SmoA1 mouse line [24]. However, Bax deletion did not accelerate 
the already rapid tumorigenesis of Math1-cre;SmoM2 mice.
We examined the effect of Bax deletion on survival after xRT by comparing the survival of 
radiated mice with M-Smo or M-Smo;Baxfloxed genotypes. Event-free survival was 
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significantly shorter in xRT-treated M-Smo;Baxfloxed mice and resembled the survival of M-
Smo mice without treatment (Figure 4A). Consistent with a lack of clinical benefit, we 
found no significant difference in the event-free survival of treated and untreated M-
Smo;Baxfloxed mice (n=10;Log Rank p=0.76). Fractionated xRT, administered as five doses 
of 2Gy similarly failed to extend the survival of M-Smo;Baxfloxed mice, which showed 
significantly shorter survival compared to M-Smo mice treated with 5 doses of 2Gy (Figure 
4A’). These data show that Bax was required for xRT to impart a clinically significant 
benefit.
To confirm that Bax deletion did not alter the induction of DNA damage or p53 activation, 
we examined γH2AX and p53. In 3/3 replicate pups of both M-Smo;BaxWT and M-
Smo;Baxfloxed mice, xRT produced extensive DNA double strand breaks, demonstrated by 
γH2AX (Figure 4B–D). This DNA damage produced equivalent phosphorylation of p53 
(Figure 4E–G). Unlike M-Smo;BaxWT tumors, M-Smo;Baxfloxed tumors did not undergo 
synchronous apoptosis 4 hours after xRT as indicated by relatively little induction of caspase 
3 cleavage (Figure 4H–M) or TUNEL staining (Figure 4N–P). In the absence of Bax-
dependent apoptosis neither DNA damage per se, nor the resulting p53 engagement were 
sufficient to cause widespread cell death or to extend mouse survival.
To test the possibility that radiation-induced cell death was delayed, rather than prevented in 
Bax-deleted tumor cells, we examined tumors at greater intervals after treatment, 
specifically 5 days after single fractions 10Gy or at the end of 5 daily fractions of 2 Gy. 
Medulloblastomas with intact Bax typically decreased in size within 48 hours after xRT and 
reached a minimum tumor size by 5 days. In contrast, Bax-deficient tumors consistently 
persisted as large masses (Figure 5A–C). 48 hours after 10Gy xRT, only scattered cells in 
M-Smo;Baxfloxed tumors demonstrated caspase 3 cleavage (Figure 5D) and scattered cells 
underwent non-apoptotic cell death, identified by positive TUNEL staining and negative 
staining for cleavage of caspase 3 (Figure 5D,G). 5 days after xRT, neither cC3 nor TUNEL 
demonstrated increased cell death (Figure 5 D–I). These results show that latent cell death in 
Bax-deleted tumors was not widespread and did not significantly disrupt tumor growth.
We further investigated whether the cytotoxic effect of chemotherapy required intact 
apoptotic pathways. We compared DNA damage and apoptosis in M-Smo;Baxfloxed and M-
Smo;BaxWT littermates 8 hours after IP etoposide injection (n=3 for each group). Etoposide 
caused extensive DNA damage in tumors of all treated mice (data not shown). BaxWT 
tumors demonstrated with extensive apoptosis, whereas in M-Smo;Baxfloxed tumors cell 
death was markedly reduced (Fig 5J,K). Thus, Bax is necessary for apoptosis in response to 
diverse, DNA-damaging therapies.
Apoptosis-deficient tumor cells resolve after treatment into terminally differentiated and 
proliferating populations
Examination of replicate M-Smo;Baxfloxed tumors at successive intervals after treatment 
demonstrated the fate of radiated tumor in the absence of apoptosis. Although xRT did not 
slow the progression of M-Smo;Baxfloxed tumors, we noted significant changes in tumor 
pathology. In 3/3 M-Smo;Baxfloxed tumors we found that the xRT-induced phosphorylation 
of H2AX resolved by 48 hours, indicating that medulloblastoma cells were able to repair 
Crowther et al. Page 8
Cancer Res. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
radiation-induced DNA double strand breaks when apoptosis was blocked (Figure 6A,B). By 
48 hours after xRT, all 3 Bax-deleted tumors demonstrated histologic changes indicating 
widespread differentiation. Tumor cells became less densely packed, elaborated eosinophilic 
neuropil and formed abundant Homer-Wright rosettes (Figure 6C,D). Consistent with 
terminal differentiation along the expected trajectory of neural progenitors, a large 
subpopulation within all 3 M-Smo;Baxfloxed tumors radiated tumors strongly up-regulated 
the neuronal marker NeuN (Figure 6E,F).
Despite the widespread differentiation induced by xRT, M-Smo;Baxfloxed tumors 
consistently progressed. Prior studies of RCAS-induced medulloblastomas in mice have 
shown that these tumors harbor a subpopulation in the perivascular regions that resumes 
proliferation within 72 hours of treatment with 2Gy xRT [20]. We did not find similar early 
recurrence after 10Gy in M-Smo mice with intact p53 and Bax. In M-Smo;Baxfloxed tumors, 
however, we found that perivascular cells resumed proliferation after a period of quiescence. 
In 3/3 M-Smo;Baxfloxed mice examined 4 hours after xRT, the p53 target p21 was 
specifically up-regulated in tumor cells along capillaries (Figure 7A). Expression of p21 
persisted through 24 hours, and during this period no cells expressing the proliferation 
marker PCNA were detected (n = 3). By 48 hours after xRT, 4/6 tumors examined contained 
PCNA+ cells. In all four tumors, these cells were predominantly located in the perivascular 
regions (Figure 7B). Double labeling for PCNA and the differentiation marker p27 
demonstrated that proliferating and differentiating tumor cells resolved spatially into discrete 
regions, with proliferation along blood vessels and differentiation further from the 
perivascular space (Figure 7C). All 9 radiated, M-Smo;Baxfloxed mice in the survival study 
that were harvested at the time of tumor progression demonstrated abundant PCNA+ tumor 
cells, indicating that after a latent period, proliferation consistently resumed. Taken together, 
these data show that a proliferative subpopulation, traceable to the perivascular regions, 
drives tumor recurrence after xRT in our model. These perivascular cells were subject to 
p53-mediated transcriptional changes, but in the absence of apoptosis, the activation of p53 
did not produce lasting therapeutic effects through either non-apoptotic cell death or 
sustained growth arrest.
To examine the tendency of tumor cells to enter and to exit the cell cycle after xRT, we 
labeled cells at S phase at 2 discrete time points, using incorporation of BrdU and EdU. M-
Smo;Baxfloxed mice were injected with BrdU 5 days after xRT, and then injected with EdU 2 
days later. Mice were harvested 4 hours after EdU injection. In 3/5 mice, we found that 
BrdU injection labeled a large number of tumor cells. In all 5 of these tumors, EdU label 
was also strongly detectable. In these 5 tumors, we consistently found that the set of BrdU+ 
cells included both EdU+ and EdU- negative cells, while all EdU+ cells were also BrdU+ 
(Figure 7D–F). The presence of BrdU+ cells that were EdU+ indicates that cells that were 
cycling 5 days after xRT gave rise to progeny that continued to divide. The presence of BrdU
+ cells that were EdU- cells indicates that some of the progeny of cells dividing 5 days after 
xRT either exited the cell cycle or proliferated more slowly.
To immunophenotype the BrdU+ tumors cells, we double labeled sections with antibodies to 
BrdU and either NeuN, PCNA or stem cell marker Sox2. Sox2 expressing cells have been 
associated with tumor recurrence in human medulloblastoma and have been shown to 
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behave as tumor stem cells, recapitulating recurrent medulloblastoma in Ptc mice treated 
with Ara-C [25]. We found in all 5 of the radiated, M-Smo;Baxfloxed mice with BrdU+ 
tumors, the BrdU labeled population included both NeuN+ and PCNA+ subpopulations 
(Figure 7G–L) indicating that cells that proliferate in the early period after xRT behaved like 
stem cells, giving rise to both differentiating and self-renewing progeny. Consistent with the 
neural stem cell phenotype, tumor cells that incorporated BrdU 5 days after xRT were 
predominantly Sox2+ 2 days later in all 5 mice examined (Figure 7 M–O). These results 
demonstrate that tumor stem cells that do not undergo apoptosis after xRT retain a 
proliferative capacity despite activation of p53. Considered against the more durable 
therapeutic response to cranial xRT in M-Smo tumors with intact p53 and Bax, the 
recurrence pattern after xRT in Bax-deficient medulloblastomas highlights the importance of 
inducing apoptosis in the stem cell population.
Discussion
Medulloblastoma is, on average, remarkably responsive to conventional treatment with xRT 
and chemotherapy. This susceptibility was discovered empirically, and the molecular basis 
for this susceptibility has not been defined. We have investigated the molecular mechanisms 
of treatment response in spontaneous medulloblastomas in transgenic, SmoM2 mice. We 
found that xRT produced a survival benefit in our model only when it activated a p53-
dependent transcriptional response that induced apoptosis.
Medulloblastomas with conditional deletion of p53 were highly resistant to xRT. In these 
tumors, xRT did not induce either the pro-apoptotic or cell cycle regulatory arms of the p53-
associated transcriptional response, demonstrated respectively by a lack of PUMA and p21 
up-regulation after xRT. Consistent with the absence of these molecular events, tumors with 
p53 deletion did not undergo treatment-related apoptosis and resumed proliferation within 
24 hours after treatment.
Medulloblastomas with Bax deletion were equally radiation resistant, despite having intact 
p53. The absence of apoptosis after xRT in these tumors made it possible to discern p53-
dependent effects that would otherwise have been obscured by widespread cell death. Unlike 
p53-deficient tumors, radiated Bax-deficient tumors resolved into 2 distinct populations, as 
tumor cells either terminally differentiated or continued to proliferate. Terminally 
differentiated tumor cells expressed neuronal markers and formed Homer-Wright rosettes. 
Although rosettes are commonly observed in human medulloblastoma, the exaggerated 
abundance of rosettes in radiated M-SmoBaxfloxed tumors recalls the histologic appearance 
of the highly malignant pediatric brain tumor known as Embryonal Tumor with Multilayered 
Rosettes (ETMR) [26]. Despite the increased differentiation of radiated, Bax-deleted 
medulloblastoma, these tumors progressed as rapidly as untreated tumors, due to the rapid 
growth of the proliferative component.
Paired BrdU/EdU experiments and immunophenotyping of BrdU+ tumor cells demonstrated 
the proliferative tumor cells that drove recurrence behaved as stem cells, giving rise to 
differentiating progeny and self-renewing proliferators. Prior investigations subjecting 
RCAS-induced, primary mouse medulloblastomas to 2Gy xRT showed that tumor stem cells 
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in the perivascular niche resumed proliferation within 72 hours of treatment [20]. We found 
that 10Gy xRT was sufficient to prevent early recurrence in M-Smo tumors, but only when 
the functions of both p53 and the intrinsic apoptotic pathway remained intact.
In mice with intact p53, Bax deletion allowed cells throughout the tumor to survive xRT. 
While p53 activation induced terminal differentiation in most cells of radiated, Bax-deficient 
tumors, perivascular stem cells did not undergo prolonged cell cycle arrest after treatment. 
The up-regulation of p21 in perivascular cells after xRT demonstrated that radiation 
provoked a p53-mediated response. In the absence of apoptosis, this p53-mediated 
transcriptional response was unable to prevent perivascular stem cells from repopulating the 
tumors. Thus perivascular stem cells were resistant to the p53-mediated cell cycle exit that 
led to differentiation outside of the perivascular regions. Taken together with the prior 
studies using lower dose xRT [20], our studies show that effective tumor treatment requires 
control of perivascular stem cells, through a dose of xRT that is sufficient to produce stem 
cell death through the intrinsic apoptotic pathway.
While we found that p53 function is required for response to xRT in our model, the 
relationship observed in medulloblastoma patients between p53 mutation and recurrence 
after therapy is complex [27–29]. Most medulloblastomas are radiosensitive and most 
medulloblastomas are p53 wild-type. Prior studies have shown in other tumors that p53 
function is required for the susceptibility of cancer cells to DNA-damaging therapies [18, 
19
, 
30
–
33]. In medulloblastoma patients, the effect of p53 mutation has depended on 
molecular subgroup. In the SHH subgroup of medulloblastoma, tumors with p53 mutation 
are significantly more likely to recur after treatment; in contrast, in the WNT subgroup, p53 
mutation is not associated with recurrence [34]. All of the p53 mutations detected in these 
studies, however, were missense mutations, rather than deletions. Moreover, the mutations 
associated with the WNT and SHH subgroups were not equivalent. Specific mutant alleles 
may retain varying degrees of residual p53 function, and may also produce gains of function 
that affect prognosis [35]. Our model shows that complete loss of p53 function confers 
radiation resistance, consistent with the worse prognosis of Shh subgroup patients with 
mutant p53. The consequences of p53 missense mutations in human medulloblastoma must 
be interpreted in light of the subgroup context, the degree of residual p53 activity and 
potential gain of function.
We propose that loss of competence for apoptosis, downstream of p53, is a significant 
source of resistance to therapy. With variable impact and an overall frequency of about 5%, 
p53 mutations cannot account for the 20% rate of medulloblastoma recurrence. We found 
that even in tumors with intact p53, a single mutation in the apoptosis pathway is sufficient 
to cause radiation resistance. While Bax mutations have not been identified in 
medulloblastoma sequencing studies [36, 37] and Bax protein is consistently detected in 
patient-derived medulloblastoma samples [24], obstruction of apoptosis may be 
accomplished in cancer through diverse mechanisms, including up-regulation of anti-
apoptotic Bcl-2 homologs and activation of Akt. Our previous finding that Bcl-2 expression 
correlates inversely with spontaneous apoptosis in patient-derived medulloblastoma samples, 
shows that Bax-dependent cell death is actively modulated by other proteins. Thus although 
Bax deletion does not directly model a genetic change seen in human medulloblastoma, the 
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principle demonstrated by Bax deletion, that apoptosis is required for treatment sensitivity, 
remains highly relevant. Moreover, this principle may be generalizable to other cancers, 
where inactivating frameshift mutations in Bax have been identified, including human colon 
cancer, gastric cancer and high grade glioma [38–41]. Our data indicate that any mutation or 
post-translational event that impairs the internal apoptotic pathway can confer treatment 
resistance.
Differentiation after DNA-damaging therapies has been observed in diverse cancers [42, 43]. 
We show that the combination of genotoxic stress, functional p53 and impaired apoptosis is 
sufficient to induce abundant differentiation, as xRT provoked neural differentiation in 
tumors with intact p53 and Bax deletion. We previously noted abundant intra-tumor 
differentiation in untreated, Bax-deficient medulloblastomas in the more slowly tumorigenic, 
ND2:SmoA1 mouse line; we interpreted terminal differentiation as an alternative fate choice 
for apoptosis-incompetent tumor cells with DNA damage that prevented continued 
proliferation [24]. In these untreated tumors, we ascribed DNA damage to replication stress. 
A similar histologic pattern was previously described in untreated medulloblastomas 
generated through simultaneous deletion of PTEN and overexpression of Shh [20]. In these 
tumors, PTEN loss caused activation of Akt, which may, like Bax deletion, effectively block 
apoptosis [44]. Taken together, these data show that the presence of differentiation in a 
tumor specimen, particularly after treatment, is not necessarily evidence of benign prognosis 
but rather may indicate defective apoptosis and increased risk of recurrence.
The similarity between radiated M-Smo;Baxfloxed medulloblastoma and ETMR suggests the 
possibility of a common mechanism. ETMR, like Bax-deleted medulloblastoma, is highly 
resistant to treatment. The pathogenesis of ETMR has been related to a fusion of the TTYH1 
promoter with the C19MC microRNA cluster, ultimately leading to aberrant DNA 
methylation [45]. The mechanism of ETMR treatment resistance, however, is not known. 
Changes in DNA methylation, however, may plausibly alter the capacity for apoptosis, for 
example by changing the expression of key apoptosis-regulating proteins. Our data suggest 
that apoptosis resistance in the setting of genomic instability can produce differentiated 
pathology along with poor prognosis and should be suspected in malignant tumors such as 
ETMR that show abundant differentiation.
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Figure 1. Medulloblastomas in M-Smo mice are radiation sensitive
A,A’) Kaplan Meier curves demosntrated that xRT extends the survival of medulloblastoma-
bearing mice. B–E) H&E stained sections of representative tumors harvested at the indicated 
interval after xRT. Tumors reduction is detectable 24 hours after xRT and is maximal by 5 
days. F–I) IHC for γH2AX shows that cells with detectable DNA damage are rare in 
untreated tumors; xRT induces homogeneous γH2AX expression at 4 hours after xRT, that 
resolves by 24 hours. J–M) IHC for cC3 shows that apoptotic cells are rare in untreated 
tumors. Radiation induces widespread apoptosis by 4 hours after treatment. Apoptosis 
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continues through 24 hours after xRT. By 5 days, apoptotic cells are rare within the residual 
tissue that persists after xRT. Scale bars are 1mm in low power images and 20 µm in insets.
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Figure 2. Increased expression of p53 targets mediating apoptosis and cell cycle arrest after xRT
A) Quantification of mRNA abundance after xRT based on expression microarray data. B) 
The five most enriched gene sets from the genes with increased expression using GSEA 
analysis (see supplementary table 1). C) Comparison of mRNA abundance change after xRT 
among indicated gene sets (see supplementary table 2). P-values are estimated by 
permutation. D) Fold change in the abundance of mRNA for Puma, p21 and GAPDH when 
radiated and untreated M-Smo tumors are compared (n=3 for each group). Abundance of 
mRNA was measured by quantitative RT-PCR and normalized to the abundance of β2 
Microglobulin (B2M) mRNA. Puma and p21 are induced by xRT, while GAPDH abundance 
is not significantly altered.
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Figure 3. Conditional deletion of p53 abrogates the treatment response to xRT
A,B) IHC for p53 demonstrates accumulation of p53 protein 2 hours after xRT in M-Smo 
tumors with intact p53. C,D) In M-Smo;p53floxed tumors, p53 is absent in tumor cells but 
detectable in adjacent stroma and in endothelial cells within the tumors. E–J) In situ 
hybridization demonstrates mRNA for Puma and p21 as indicated. Both Puma and p21 
mRNAs are induced by xRT in M-Smo tumors. Post-xRT expression of Puma and p21 is 
reduced in tumors with conditional deletion of p53. K–M) Cleavage of caspase 3 is not 
induced in M-Smo;p53floxed tumors by xRT at either 4 hours, 24 hours or 5 days after 
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treatment. N–P) IHC for PH3 demonstrates mitotic figures. M-Smo;p53floxed tumors 
demonstrate absence of mitosis 4 hours after xRT, but demonstrate frequent mitoses 24 
hours and 5 days after treatment. Scale bars: 1mm (A,C and K–P), 100 µm (B,D and E–J), 
and 50 µm (insets).
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Figure 4. Medulloblastomas with Bax deletion are resistant to xRT despite activation of p53
A,A’) Kaplan Meier curves compare the survival of radiated M-Smo;Baxfloxed mice to 
radiated and untreated M-Smo mice. Log Rank analysis shows that the difference in the 
survival of radiated mice with intact or deleted alleles of Bax is statistically significant. B–
G) xRT induces γH2AX (B–D) and phosphorylation of p53 (E–G) in medulloblastomas of 
both M-Smo and M-Smo;Baxfloxed mice. H–M) IHC for cC3 demonstrates that apoptosis is 
strongly induced by xRT in M-Smo tumors, but greatly reduced in M-Smo;Baxfloxed tumors. 
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N–P) TUNEL staining similarly demonstrates that cell death after xRT is greatly reduced in 
tumors with Bax deletion. Scale bars: 50 µm (B–-G and K–P), 100 µm (H–J).
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Figure 5. Absence of cell death in medulloblastoma with Bax deletion after xRT or 
chemotherapy
A–C) H&E stained sections of representative, radiated M-Smo;Baxfloxed tumors at (A) 48 
hours after 10 Gy, (B) 5 days after 10 Gy, and (C) after 5 daily doses of 2Gy consistently do 
not demonstrate tumor regression typical of medulloblastoma with intact Bax. D–I) cC3 and 
TUNEL staining do not demonstrate widespread apoptosis at the indicated interval after 
treatment. J,K) IHC for cC3 shows apoptosis in an M-Smo tumor 8 hours after etoposide 
treatment. Markedly less apoptosis is induced by etoposide in a representative M-
Smo;Baxfloxed tumor. Scale bars: 500 µm (A–C and J,K), 50 µm (D–I).
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Figure 6. Radiation induced changes in Bax-deleted medulloblastomas: DNA repair and 
neuronal differentiation
A,B) γH2AX, strongly detectable 4 hours after xRT resolved by 48 hours, consistent with 
effective DNA repair. C,D) Between 4 and 48 hours after xRT, M-Smo;Baxfloxed 
medulloblastomas developed a differentiated histology, marked by the elaboration of 
eosinophilic neuropil and the formation of Homer Wright rosettes. E,F) IHC for NeuN 
demonstrates the dramatic increase in NeuN expression that was consistently seen 48 hours 
after radiation of Bax-deleted tumors. Scale bars: 100 µm (A–D and insets), 1 mm (E,F).
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Figure 7. In apoptosis-deficient tumors, xRT fails to prevent the growth of perivascular stem cells 
that drive recurrence
A) IHC demonstrates p21 up-regulation specifically in cells of the perivascular region 
(arrowhead) 4 hours after xRT. B) 48 hours after xRT, cells of the perivascular region 
(arrowhead) express proliferation marker PCNA. C) Double labeling with antibodies to 
PCNA and differentiation marker p27 demonstrates proliferation in the perivascular region 
(arrowheads) and differentiation further from the vessels. D–F) BrdU injected 5 days after 
xRT labels a subpopulation of tumor cells in a representative M-Smo;Baxfloxed tumor. EdU 
injection 2 hours prior to harvest labels an overlapping subpopulation. All EdU+ cells were 
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BrdU+, indicating that cells proliferating 7 days after xRT descend from cells proliferating 2 
days earlier. Some BrdU+ cells were EdU- consistent with a portion of BrdU+ cells having 
left the cell cycle. G–I) In the same tumor, a portion of BrdU+ cells express NeuN (yellow 
arrows), consistent with neuronal differentiation. J–L) In the same tumor, numerous BrdU+ 
cells are PCNA+, indicating continued proliferation. M–O) BrdU+ cells were predominantly 
Sox2+, consistent with a stem cell phenotype. Scale bars: 100 µm (A–C), 50 µm (D–O).
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